Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

DR-0201 · SAR448501

Bispecific antibody · Modulator of CD20 (MS4A1) · developed by Sanofi

Phase 1 Most advanced trial
SNY Developer

What is DR-0201?

DR-0201 (SAR448501) is a bispecific monoclonal antibody that binds CD20 on the surface of B cells. It blocks CD20-mediated signaling and can trigger phagocytosis of CD20-expressing cells by macrophages, depleting pathogenic B cells. It is being studied in systemic lupus erythematosus and rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR448501
Drug type
Bispecific antibody
Targets
CD20 (MS4A1)
Mechanism
Modulator of CD20 (MS4A1)
Pathways
CD20-mediated signaling blockade, macrophage-mediated phagocytosis of CD20-overexpressing cells, B-cell depletion
Therapy area
Immunology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)

Other drugs acting on MS4A1

More from Sanofi

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind DR-0201

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.